Spain’s AEMPS clarifies position on hydroxychloroquine, echoing statements of EMA and Lancet

Published date06 June 2020
Subject MatterClinical Trials,Coronavirus/COVID-19,European Medicines Agency (EMA),Research and Development,Spain,Regulatory Oversight,Life Sciences,Pharmaceutical Industry,Regulatory Agenda
AuthorÁlvaro Abad
Law FirmHogan Lovells

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT